Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

A 68-year-old man comes to the clinic for a routine follow-up examination. He has a history of nonvalvular atrial fibrillation, heart failure with reduced ejection fraction (LVEF 35%), and hyperlipidemia. One month ago, he was diagnosed with active pulmonary tuberculosis and was started on a standard four-drug regimen consisting of rifampin, isoniazid, pyrazinamide, and ethambutol. His other daily medications include apixaban, lisinopril, carvedilol, and atorvastatin. Vital signs today are temperature 37.0°C (98.6°F), blood pressure 122/80 mmHg, heart rate 72/min, and respiratory rate 16/min. Physical examination is unremarkable. Laboratory studies, including renal and hepatic function panels, are within normal limits. Which of the following is the most appropriate modification to this patient's pharmacologic regimen?

  1. Transition apixaban to warfarinCevap
  2. B
    Transition apixaban to rivaroxaban
  3. C
    Add aspirin to the current regimen
  4. D
    Discontinue pyrazinamide and ethambutol
  5. E
    Transition carvedilol to diltiazem

Cevap

The most appropriate modification is to transition the patient from apixaban to warfarin.
The patient is taking rifampin, a potent inducer of the cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter. Apixaban, a direct oral anticoagulant (DOAC), is metabolized by CYP3A4 and is a substrate for P-gp. Concomitant use of rifampin significantly decreases apixaban plasma concentrations, leading to subtherapeutic anticoagulation and an increased risk of cardioembolic stroke. When patients require concurrent treatment with strong CYP3A4/P-gp inducers, DOACs are generally avoided as empiric dose adjustments are not validated or recommended. The most appropriate strategy is to transition the patient to warfarin. Although warfarin metabolism (primarily via CYP2C9) is also induced by rifampin, its anticoagulant effect can be safely and accurately titrated using routine International Normalized Ratio (INR) monitoring.

Adım Adım Çözüm

1
Identify the critical drug-drug interaction in the patient's current medication regimen.
Rifampin is a potent inducer of CYP3A4 and P-glycoprotein, which will significantly reduce the serum concentration of apixaban.
Recognizing pharmacokinetic interactions is essential to prevent therapeutic failure, which in this case would leave the patient at a high risk for a cardioembolic stroke.
2
Determine the appropriate alternative anticoagulant for stroke prophylaxis.
Warfarin is selected because its anticoagulant effect can be directly measured and titrated via the International Normalized Ratio (INR).
Although warfarin metabolism is also induced by rifampin, the ability to monitor INR allows the clinician to safely increase the warfarin dose to maintain therapeutic anticoagulation, unlike direct oral anticoagulants which lack standardized monitoring parameters.

Anahtar Kavram

Direct oral anticoagulants (DOACs) are contraindicated with potent CYP3A4 and P-glycoprotein inducers like rifampin due to decreased drug efficacy; warfarin is preferred because its dose can be reliably titrated based on INR monitoring.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru